Agenda

 

 

Washington, D.C., 7 - 8 November 2019

Schedule

Create your personal agenda –check the favourite icon

Nov 708:40
Conference pass

Keynote Address: A vision for a healthy antibiotic R&D ecosystem

Plenary
Kevin Outterson, Professor, Boston University & Executive Director, CARB-X
Nov 709:00
Conference pass

Keynote address: UK’s efforts to combat resistance and create a sustainable commercial environment for existing and future antibiotics

Plenary
Jonathan Van-Tam, Deputy Chief Medical Officer, UK Department of Health
Nov 709:20
Conference pass

Sponsored keynote address

Plenary
TITLE SPONSOR SLOT
Nov 709:40
Conference pass

Open Panel & Audience Q&A: Analyzing the potential impact of current commercial and “pull” initiatives

Plenary
Kevin Outterson, Professor, Boston University & Executive Director, CARB-X
Jeremy Knox, Senior Investment Director, Wellcome Trust
Melissa Stundick, Executive Director, Strategic Alliances, Spero Therapeutics
Aleks Engel, Director, REPAIR Impact Fund, Novo Holdings
Evan Loh, Chairman, Antimicrobials Working Group, President, Chief Operating Officer, Chief Medical Officer, Paratek Pharmaceuticals , Inc.
Nov 711:15
Conference pass

How BARDA Incentivizes antibacterial development from early development through marketing approval

Antibiotic R&D
Mark Albrecht, Branch Chief (Acting), Antibacterials Program, BARDA
Nov 711:15
Conference pass

Stewardship eff orts among generic antibiotic manufacturers - Uniting generics through AMR Industry alliance to increase global stewardship

Antimicrobial Stewardship
Giancarlo Francese, Access Head, Social Impact and Responsibility, Teva
Nov 711:15
Conference pass

Diagnostic devices for antimicrobial susceptibility and resistance - FDA update on recent initiatives and advancements

Diagnostics
Ribhi Shawar, Branch Chief, Division of Microbiology, CDRH OIVD, FDA
Nov 711:15
Conference pass

CARB-X – Accelerating innovation to fight drug-resistant bacteria

Pitch and Partner
Karen Gallant, Research and Development Chief (Acting) and Voting member of the Joint Oversight Committee,, CARB-X
Nov 711:15
Conference pass

Infection Control in Africa: preventing infections in African health facilities through laws and standards

Infection Control
Jay K Varma, Senior Advisor, Africa Centers For Disease Control And Prevention
Nov 711:15
Conference pass

Ensuring a sustained availability of high-quality antibiotics - Considerations for manufacturing, quality testing, transport, poor quality drugs, and the role of customers

Manufacturing
Jaideep Gogtay, Senior Vice President, Global Chief Medical Officer, Cipla
Nov 711:35
Conference pass

Oral Ceftriaxone - a proof-of-concept for a novel drug delivery platform

Antibiotic R&D
Nov 711:35
Conference pass

Big data to improve antibiotic prescribing: CVS Health-Aetna’s multi-stakeholder approach

Antimicrobial Stewardship
Daniel Knecht, Vice President of Health Strategy & Innovation, CVS Health
Nov 711:35
Conference pass

Session details to be announced

Diagnostics
More information available soon
Nov 711:35
Conference pass

Utilizing Bacteriophages to Prevent Infections: An Update

Pitch and Partner
Mark Engel, Chief Executive Officer, Phagelux
Nov 711:35
Conference pass

Determining your Hospital’s Infection Control protocols and ensuring facility-wide compliance

Infection Control
Balancing hospital resources, expertise and with regulatory standards.
Nov 711:35
Conference pass

Collaborating along the value chain for sustainably-made antibiotics: roles of manufacturers and buyers

Manufacturing
Alba Tiley, Head of Sustainability, Centrient
Nov 711:55
Conference pass

How degrading residual antibiotics in the GI tract may prevent the emergence of anti-microbial resistance in the gut microbiome

Antibiotic R&D
Sheila Connelly, Vice President of Research, Synthetic Biologics
Nov 711:55
Conference pass

Real world data generated global product registries

Antimicrobial Stewardship
The next stage of industry antibiotic stewardship to promote responsible and sustainable use of our antibiotics.
Nov 711:55
Conference pass

Developing phage drugs as first-line therapies

Pitch and Partner
Alexander Belcredi, Chief Executive Officer, PhagoMed Biopharma
Nov 711:55
Conference pass

Current state by state regulations for hospital infection reporting, safety and infection control standards, and reality of nation-wide regulations for hospital infection reporting?

Infection Control
Speaker to be announced.
Nov 711:55
Conference pass

Synthesizing complex molecules for antibacterial products – manufacturing challenges and opportunities

Manufacturing
Jacques Dumas, Chief Scientific Officer, Tetraphase Pharmaceuticals
Nov 712:05
Conference pass

Overcoming bacterial resistance through a new and unique mode of action

Pitch and Partner
Malcolm Thomas, Chief Executive Officer, Agile Sciences, Inc.
Nov 712:15
Conference pass

GOLD SPONSOR SESSION

Antibiotic R&D
If you are interested in sponsoring this session, contact André Singer now at+1 646 619 1797 or andre.singer@terrapinn.com
Nov 712:15
Conference pass

GOLD SPONSOR SESSION

Antimicrobial Stewardship
If you are interested in sponsoring this session, contact André Singer now at+1 646 619 1797 or andre.singer@terrapinn.com
Nov 712:15
Conference pass

GOLD SPONSOR SESSION

Diagnostics
If you are interested in sponsoring this session, contact André Singer now at+1 646 619 1797 or andre.singer@terrapinn.com
Nov 712:15
Conference pass

ACX-362E and ACX-375C to treat serious and life- threatening bacterial infections

Pitch and Partner
David Luci, Chief Executive Officer, Acurx Pharmaceuticals
Nov 712:15
Conference pass

GOLD SPONSOR SESSION

Infection Control
If you are interested in sponsoring this session, contact André Singer now at+1 646 619 1797 or andre.singer@terrapinn.com
Nov 712:15
Conference pass

GOLD SPONSOR SESSION

Manufacturing
If you are interested in sponsoring this session, contact André Singer now at+1 646 619 1797 or andre.singer@terrapinn.com
Nov 712:25
Conference pass

PhageBank - Advancing personalized phage therapy from niche to broad market scale

Pitch and Partner
Greg Merril, Chief Executive Officer, Adaptive Phage Therapeutics
Nov 713:05
Conference pass

Keynote Address: What will it take to bring big pharma back into antibiotic R&D and in-licencing and what are companies currently doing to combat resistance and promote stewardship

Plenary
Jayasree K. Iyer, Executive Director, Access to Medicine Foundation
Nov 714:10
Conference pass

Roundtable: Advancing Preclinical – working with regulators through pre-clinical to advance distinct classes of small molecule drugs

Plenary
Ryan Devies, CEO, Curza
Nov 714:10
Conference pass

Roundtable: Animal Health - examining stewardship progress in managing antibiotic use and potential AMR in Animal Health

Plenary
Rick Sibbel, Former Executive Director, US Food Animal Business Unit, Merck Animal Health
Paul Plummer, Executive Director, National Institute of Antimicrobial Resistance Research and Education (NIAMRRE)
Brian Lubbers, Associate Professor, Kansas State University
Nov 714:10
Conference pass

Roundtable: Antimicrobial value assessment - a look into the role of HTA in the UK's testing of novel assessment and delinked payment program

Plenary
Colm Leonard, Consultant Clinical Advisor, The National Institute for Health and Care Excellence (NICE)
Nov 714:10
Conference pass

Roundtable: Controlling c.dif - determining who to test and how to prevent additional outbreaks in the hospital

Plenary
Kartik Cherabuddi, Director, Antimicrobial Stewardship Program and Hospital Epidemiologist, University of Florida
Nov 714:10
Conference pass

Roundtable: Customizing Epic – the use of Epic Stewardship Navigator to aid antimicrobial stewardship, pharmacist workflow, and prescribing habits in a tertiary cancer center

Plenary
Justine Ross, Infectious Diseases Pharmacist, Chair Antimicrobial Stewardship Program, Department of Pharmacy Services, City Of Hope National Medical Center
Nov 714:10
Conference pass

Roundtable: Innovation & stewardship – description to be announced

Plenary
Richard Vickers, Senior Vice President, and Chief Scientific Officer, Anti-infectives, Summit Therapeutics
Dave Powell, Head of Research and SVP, Summit Therapeutics
Nov 714:10
Conference pass

Roundtable: Market Access - overcoming access barriers for smaller markets - considerations for countries and developers

Plenary
Christine Årdal, Senior Advisor, EU-JAMRAI, Norwegian Institute of Public Health
Nov 714:10
Conference pass

Roundtable: Non-traditional antibacterials – advancing non-traditional product types from discovery phase to clinical development

Plenary
Brian Tse, Health Scientist, BARDA
Nov 714:10
Conference pass

Roundtable: Patient Advocacy - what can the growing antibiotic patient advocacy community do to generate public awareness and support for AMR initiatives

Plenary
Christian Lillis, Peggy Lillis Foundation
Nov 714:10
Conference pass

Roundtable: Policy in Africa- advancing advocacy, political commitment, resistance data collection and Africa-wide stewardship guidelines for antimicrobial use in humans

Plenary
Jay K Varma, Senior Advisor, Africa Centers For Disease Control And Prevention
Nov 714:10
Conference pass

Roundtable: Supporting Developmen

Plenary
NIH programs to fill gaps in traditional and non-traditionaltherapeutic discovery & development with grants, contracts,in-vitro and in-vivo screening and manufacturing capabilities and more.
Jane Knisely, Program Officer, NIAID, NIH
Nov 715:15
Conference pass

Novel Trial Designs for non-traditional anti-infectives – Lessons learned from the Exebacase superiority design trial

Antibiotic R&D
Cara Cassino, Chief Medical Officer and Executive Vice President of Research and Development, Contrafect Corporation
Nov 715:15
Conference pass

A coordinated approach to statewide stewardship goals

Antimicrobial Stewardship
Erica Washington, Healthcare-associated Infections and Antibiotic Resistance Program Coordinator, Louisiana Department Of Health
Nov 715:15
Conference pass

A-Z of hospital and pharmacy use of new and existing rapid diagnostics –diagnosing multi drug resistant organisms

Diagnostics
Eric Wenzler, Assistant Professor, Department of Pharmacy Practice,, University of Illinois at Chicago College of Pharmacy
Nov 715:15
Conference pass

Leveraging sources of public funding to meet gaps in S&M antibiotic financing

Pitch and Partner
How can we avoid the catastrophic disappearance of S&M companies and their unique competencies in antibiotic discovery and development.
Jean-Pierre Paccaud, Director, Business Development and Corporate Strategy, Global Antibiotic Research and Development Partnership (GARDP)
Nov 715:15
Conference pass

Screening for gram negative bacteria - When to screen, who to screen, how to screen?

Infection Control
Michelle A. Barron, Medical Director, UCH Infection Prevention and Control, Professor of Medicine, University of Colorado Denver
Nov 715:15
Conference pass

AMR manufacturing environmental update

Manufacturing
Steve Brooks, Advisor, AMR Industry Alliance
Nov 715:35
Conference pass

Working with regulators to advance non-traditional therapies to prevent and treat life-threatening infections in surgery and trauma

Antibiotic R&D
Michael P. Bevilacqua, Chief Executive Officer, Amicrobe
Nov 715:35
Conference pass

Canadian Accreditation Standards and the Nova Scotia Health Authority experience

Antimicrobial Stewardship
Kim Abbass, Antimicrobial Stewardship, Eastern Zone, Nova Scotia Health Authority
Nov 715:35
Conference pass

UK Centre of Excellence - a global resource for pre-clinical and clinical development, and mobilizing public, private and philanthropic investment

Pitch and Partner
Peter Jackson, CEO, The AMR Centre
Nov 715:35
Conference pass

C. diff and C-suite headaches; reimbursement, outbreaks, and recurrence

Infection Control
Kerry Laplante, President, Society of Infectious Diseases Pharmacists (SIDP), Professor of Pharmacy, University of Rhode Island, Adjunct Profess, Society of Infectious Disease Pharmacists, Brown University
Nov 715:55
Conference pass

PANEL: efforts to tackle the toughest clinical trials for antibiotic development - HABP/VABP & blood stream infections and more

Antibiotic R&D
Marina Kozak, Biologist, Division of CBRN Countermeasures, BARDA
Pamela Tenaerts, Executive Director, Clinical Trials Transformation Initiative
Vance Fowler, Professor in Molecular Genetics and Microbiology,, Duke Clinical Research Institute, Duke University Medical Center
Nov 715:55
Conference pass

When and how to prescribe new agents - best practices for understanding resistance and effectiveness of new antibiotics

Antimicrobial Stewardship
Liza Vaezi, Co-Director Antimicrobial Stewardship Program, Virginia Mason Medical Center, Clinical Associate Professor, University Of Washington
Nov 715:55
Conference pass

PANEL: Evaluating novel diagnostics for hospital use and uptake in the clinic– considerations for cost, personnel training, and microbiologist collaboration

Diagnostics
Moderator: available for sponsorship.
Neil Clancy, Associate Professor of Medicine, Infectious Diseases Division, and Director, Mycology Program, University of Pittsburgh
Fatima Brakta, Pharmacy Clinical Manager, University Medical Center of New Orleans
Ed Septimus, Professor Internal Medicine, Texas A&M Health Science Center
Nov 715:55
Conference pass

XF-73 for the prevention of post-surgical staphylococcal infections

Pitch and Partner
Neil Clark, Chief Executive Officer, Destiny Pharma Ltd
Nov 715:55
Conference pass

Isolation - when to isolate, who to isolate - Is healthcare moving away from isolation?

Infection Control
Daniel Morgan, Associate Professor of Epidemiology and Medicine, University of Maryland School of Medicine
Nov 715:55
Conference pass

Environmental exposure, risk assessment and dissemination of AMR - comparing global regions and current waste management practices

Manufacturing
Speaker to be announced.
Nov 716:05
Conference pass

A novel immunotherapy to fight infection and inflammation

Pitch and Partner
Rusty Bromley, Chief Operating Officer, AyuVis research, Inc.
Nov 716:15
Conference pass

GOLD SPONSOR SESSION

Antimicrobial Stewardship
If you are interested in sponsoring this session, contact André Singer now at+1 646 619 1797 or andre.singer@terrapinn.com
Nov 716:15
Conference pass

Antabio SAS: novel antibacterials targeting critical priority MDR gram-negative pathogens

Pitch and Partner
Marc Lemonnier, Chief Executive Officer, Antabio
Nov 716:15
Conference pass

GOLD SPONSOR SESSION

Infection Control
If you are interested in sponsoring this session, contact André Singer now at+1 646 619 1797 or andre.singer@terrapinn.com
Nov 716:15
Conference pass

GOLD SPONSOR SESSION

Manufacturing
If you are interested in sponsoring this session, contact André Singer now at+1 646 619 1797 or andre.singer@terrapinn.com
Nov 716:25
Conference pass

Session to be announced

Pitch and Partner
Speaker to be announced.
Nov 717:15
Conference pass

Keynote Panel: Benchmarking and Risk-Adjusting Antimicrobial Use: Success, Barriers, and Future

Plenary
Eddie Stenehjem, Medical Director, Antibiotic Stewardship, Intermountain Healthcare
Clifford McDonald, Associate Director for Science, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious, Centers for Disease Control and Prevention
Rebekah Moehring, Associate Professor of Medicine, Department of Medicine, Duke University
Matthew Goetz, Chief of Infectious Diseases, V.A. Greater Los Angeles Healthcare System
Adam Zerda, Director, AMR Strategy and Development, Becton Dickinson
Kalvin Yu, Medical Director, BD Digital Health MedMined, Becton Dickinson

Create your personal agenda –check the favourite icon

Nov 809:00
Conference pass

Keynote Address: Patient and public outcry – examining the human impact of AMR and how we can make it a mainstream issue

Plenary
Mary Millard, Patient Advocate, Sepsis Survivor
Christian Lillis, Peggy Lillis Foundation
Nov 809:25
Conference pass

Keynote Address

Plenary
Title Sponsor.
Nov 809:50
Conference pass

Keynote address: 360 of hospital purchasing and antibiotic use – Understanding price-based vs stewardship-based purchasing decisions for new antibiotics & diagnostics

Plenary
Debbie Goff, Infectious Diseases Specialist, College of Pharmacy, Ohio State University Medical Center
Andrew Shorr, Head of Pulmonary and Critical Care Medicine, Washington Health Center
Jason Pogue, President-Elect, Society of Infectious Disease Pharmacists, Brown University
Nov 811:15
Conference pass

Pilot reimbursement models to ensure access of new antibiotics in Sweden - Collaboration between industry and government agencies to ensure a model that works for all stakeholders

Antibiotic R&D
Jenny Hellman, Analyst, Public Health Agency of Sweden
Nov 811:15
Conference pass

Pharmacists on the front lines of outpatient care- Examining the critical role pharmacists & point of care diagnostics play in appropriate outpatient antibiotic use

Antimicrobial Stewardship
Charley John, Director, US Public Policy, Walgreen Co.
Nov 811:15
Conference pass

Reversing the “pitch” between diagnostics providers and industry

Diagnostics
Benefits and feasibility of pharma communicating their needs diagnostic developers first to accelerate development of badly needed tests.
Mary Motyl, Director of Clinical Microbiology, Merck
Nov 811:15
Conference pass

Investors Panel: Promising science in the field of antibiotic diagnostics and how developers can best approach investors

Pitch and Partner
Mary Schaheen, President And Director, Prevail Partners
Cristina Montero, Associate Director, TechAtlas, RA Capital Management
Walter Stockinger, Managing Partner, Hadean Ventures
Nov 811:15
Conference pass

Making sense of all the infection control guidelines for surfaces and environments in hospitals

Infection Control
Linda Lybert, Founder and Executive Director, Healthcare Surfaces Institute
Nov 811:15
Conference pass

Linking vaccine use to AMR reduction – Do we have enough evidence to convince policy makers to incorporate vaccines into broader AMR strategies

Vaccines in AMR
Jim Wassil, Business Unit Lead, Vaccines, Patient & Health Impact, Pfizer
Nov 811:35
Conference pass

Short- and long-term payment strategies for a sustainable market – impact of NTAP modifications, DRG carve-out, and potential subscription models

Antibiotic R&D
Monika Schneider, Research Associate, Margolis Center for Health Policy, Duke University
Nov 811:35
Conference pass

Urgent Care – antibiotic stewardship’s new frontier?

Antimicrobial Stewardship
Eddie Stenehjem, Medical Director, Antibiotic Stewardship, Intermountain Healthcare
Nov 811:35
Conference pass

Diagnostic engagement through antibiotic clinical development & commercialization – can further collaboration be attached to collectively tackle AMR?

Diagnostics
Speaker to be announced.
Nov 811:35
Conference pass

GOLD SPONSOR SESSION

Infection Control
If you are interested in sponsoring this session, contact André Singer now at+1 646 619 1797 or andre.singer@terrapinn.com
Nov 811:35
Conference pass

The role of vaccination in Antimicrobial Stewardship (AMS) and Merck’s One Health approach to tackling the challenge of AMR

Vaccines in AMR
Allison Flinn, Lead, North America Public Policy, Merck Animal Health
Nov 811:55
Conference pass

PANEL: How to foster private investment in antibiotic development? Exploring an impact investment fund

Antibiotic R&D
Peter Beyer, Senior Advisor, World Health Organisation
Nov 811:55
Conference pass

GOLD SPONSOR SESSION

Antimicrobial Stewardship
If you are interested in sponsoring this session, contact André Singer now at+1 646 619 1797 or andre.singer@terrapinn.com
Nov 811:55
Conference pass

GOLD SPONSOR SESSION

Diagnostics
If you are interested in sponsoring this session, contact André Singer now at+1 646 619 1797 or andre.singer@terrapinn.com
Nov 811:55
Conference pass

Quorum X Diagnostics: A new way of identifying bacteria, without the need for culture or DNA amplification

Pitch and Partner
Nov 811:55
Conference pass

PANEL: Case Study: Getting C-Suite Buy-in for new hospital infection control products and technologies - weighing risks and liabilities of taking on new infection control technologies

Infection Control
Jeffrey Silvers, Medical Director of Quality, Infection Control and Pharmacy, Sutter Health
Dennis Drapiza, Regional Director-Northwest Infection Prevention and Control, Kaiser Permanente
Nov 812:05
Conference pass

Aperture Bio empiriSTAT UTI: A rapid, direct-out-of-urine method for addressing the rise in antibiotic resistance in urinary tract infections

Pitch and Partner
Matthew Gombrich, Chief Medical Officer, Aperture Bio
Nov 812:15
Conference pass

GOLD SPONSOR SESSION

Antimicrobial Stewardship
If you are interested in sponsoring this session, contact André Singer now at +1 646 619 1797 or andre.singer@terrapinn.com
Nov 812:15
Conference pass

Bacteromic: Intelligence for precision therapies against antimicrobial resistance

Pitch and Partner
Piotr Garstecki, Board Member, Bacteromic
Nov 812:15
Conference pass

GOLD SPONSOR SESSION

Vaccines in AMR
If you are interested in sponsoring this session, contact André Singer now at+1 646 619 1797 or andre.singer@terrapinn.com
Nov 813:00
Conference pass

C-Suite Fireside Chat: Balancing continued innovation in R&D while navigating funding, stewardship and the overall commercial landscape

Plenary
Session Moderator avaialable for Gold Sponsorship.
Mike Dudley, President and Chief Executive Officer, Qpex Biopharma
Manos Perros, President & CEO, Entasis Therapeutics
Guy Macdonald, President and Chief Executive Officer, Tetraphase Pharmaceuticals
David Roblin, Chief Operating Officer, Chief Medical Officer And President Of Research And Development, Summit Therapeutics
Nov 814:10
Conference pass

Roundtable: AMR and Sepsis - we are all in this together

Plenary
Thomas Heymann, Executive Director, Sepsis Alliance
Nov 814:10
Conference pass

Roundtable: CARB-X Accelerator – Company perspective on CARB-X Accelerator - What worked and what can be improved?

Plenary
Jeanette Mucha, CEO, Chief Science Officer and Co-Founder, SciBac
Nov 814:10
Conference pass

Roundtable: Evaluating diagnostics – submission criteria for payers

Plenary
Eugean Jiwanmall, Senior Research Analyst, Technology Evaluation And Medical Policy, Independence Blue Cross (United States)
Nov 814:10
Conference pass

Roundtable: Health Technology Assessment – when it comes to AMR, will HTA be part of the solution or part of the problem?

Plenary
Abby Colson, Research Associate, University of Strathclyde Glasgow
Nov 814:10
Conference pass

Roundtable: Infection intervention - Using the microbiome to make antibiotics effective again

Plenary
Lee Jones, Founder, President and Chief Executive Officer, Rebiotix, Inc.
Nov 814:10
Conference pass

Roundtable: Infection prevention – next wave of infection prevention of multidrug resistant infections through screening, protocol and more

Plenary
Angella Browne, Infection Contol Officer, Howard University Hospital
Nov 814:10
Conference pass

Roundtable: Microbiome & CDC – Discussing a vision for precision public health novel approaches to treating infection prevention through the microbiome

Plenary
Clifford McDonald, Associate Director for Science, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious, Centers for Disease Control and Prevention
Nov 814:10
Conference pass

Roundtable: Moving policy forward – payment reform, public perception and continued efforts in 2020

Plenary
Monika Schneider, Research Associate, Margolis Center for Health Policy, Duke University
Jeremy Knox, Senior Investment Director, Wellcome Trust
Nov 814:10
Conference pass

Roundtable: Surveillance

Plenary
Examining novel metrics for measurement, societal and socioeconomic factors effecting resistance, and how resistance surveillance tools can help educate policymakers on AMR.
Eili Klein, Fellow, Center for Disease Dynamics Economics & Policy
Nov 814:10
Conference pass

Roundtable: The fecal microbiome - new approaches to the treatment of C. difficile infection

Plenary
Nick Van Hise, Infectious Disease Clinical Pharmacy Specialist, Research Coordinator, Metro Infectious Disease Consultants and Cdiff Foundation
Nov 815:15
Conference pass

GOLD SPONSOR SESSION

Antibiotic R&D
If you are interested in sponsoring this session, contact André Singer now at+1 646 619 1797 or andre.singer@terrapinn.com
Nov 815:15
Conference pass

GOLD SPONSOR SESSION

Antimicrobial Stewardship
If you are interested in sponsoring this session, contact André Singer now at +1 646 619 1797 or andre.singer@terrapinn.com
Nov 815:15
Conference pass

FebriDx: A POC test that simultaneously detects MxA and CRP during presumed acute respiratory infection to improve clinical workflow, reduce unnecessary antibiotics, and save costs

Diagnostics
Robert Sambursky, President And Chief Executive Officer, Rapid Pathogen Screening, Inc (RPS)
Nov 815:15
Conference pass

GOLD SPONSOR SESSION

Infection Control
If you are interested in sponsoring this session, contact André Singer now at +1 646 619 1797 or andre.singer@terrapinn.com
Nov 815:15
Conference pass

GOLD SPONSOR SESSION

Vaccines in AMR
If you are interested in sponsoring this session, contact André Singer now at +1 646 619 1797 or andre.singer@terrapinn.com
Nov 815:20
Conference pass

Discovery of Antimicrobial peptides from Alligator and Komodo Dragons against multi-drug resistant bacteria

Pitch and Partner
Monique Van Hoek, Professor School of Systems Biology, George Mason University, College of Science
Nov 815:35
Conference pass

Innovative business partnerships to build a portfolio of novel antibiotics

Antibiotic R&D
Zak Zimmerman, Chief Executive Officer, Forge Therapeutics
Nov 815:35
Conference pass

Unifying hospital ASP’s at the national level in the UAE: challenges & achievements

Antimicrobial Stewardship
Dirar Abullah, Head, Adult Critical Care Services, Chair, Antibiotic Committee and Antibiotic Stewardship Program, Prime Hospital Dubai
Nov 815:35
Conference pass

VALUE-DX: generating evidence on the medical, economic, and public health value of diagnostics in tackling AMR

Diagnostics
Herman Goossens, Project Leader, VALUE-Dx, Director of Research, Laboratory of Medical Microbiology, University Of Antwerp
Nov 815:35
Conference pass

Patient Perspective – How hospitals can and should educate patients on infection risks and easy to implement prevention practices

Infection Control
Mary Millard, Patient Advocate, Sepsis Survivor
Nov 815:35
Conference pass

A novel toxoid vaccine targeting Staphylococcus aureus virulence

Vaccines in AMR
M. Javad Aman, Chief Executive Officer, Integrated Biotherapeutics
Nov 815:55
Conference pass

Rationale for in-licensing early stage antibacterial assets

Antibiotic R&D
Terry Roemer, President and Chief Scientific Officer, Prokaryotics
Nov 815:55
Conference pass

International stewardship practices

Antimicrobial Stewardship
Speaker to be announced.
Nov 815:55
Conference pass

How to effectively educate nurses and healthcare practitioners on every day cleaning and infection prevention

Infection Control
Speaker to be announced.
Nov 816:00
Conference pass

Pitch to be announced

Pitch and Partner
Speaker to be announced.
last published: 20/May/19 21:05 GMT

 

 


GET INVOLVED AT

WORLD ANTI-MICROBIAL RESISTANCE CONGRESS

 

To Sponsor Or Exhibit

 


André Singer
andre.singer@terrapinn.com
+1 646.619.1797

 

 

Press & Media Partnerships

 


Shannon McGorry
shannon.mcgorry@terrapinn.com
+1 646.619.1840

 

 

To Speak

 


Claire Murphy
claire.murphy@terrapinn.com
+1 646.619.1784

 

Sign Up for Event Updates